Articles tagged with Breast Cancer Cells
M.D. Anderson researchers discover that low-molecular-weight (LMW-E) forms of cyclin E render aromatase inhibitor letrozole ineffective in women with estrogen-receptor-positive breast cancers. A CDK2 inhibitor can reverse letrozole resistance, offering a potential treatment option for patients.
Researchers have identified an enzyme that can remove the oncogene WT1 from cancer cells, leading to promising targets for treatments. The discovery of protease HtrA2 has shed new light on how levels of WT1 are controlled in cancer.
A study by researchers at Tufts University School of Medicine identifies two populations of progenitor cells that propose a new model for breast cell differentiation. One population appears to be the cell of origin for luminal-like breast cancer, which is sensitive to hormones and tends to grow more slowly.
Researchers identified a molecule, MMP2, that controls fibroblast growth factor (FGF) signaling in fruit flies, allowing them to study the process of tissue invasion. This finding may provide new insights into how cancer cells spread and could lead to the development of new treatments.
Researchers at Texas A&M AgriLife Communications discovered that mango polyphenols can prevent or stop growth of certain breast and colon cancer cells. The study found that the fruit's antioxidants had a significant impact on these specific types of cancer, with some cell lines undergoing programmed cell death.
A new investigational agent YC137 was found to restore sensitivity of breast cancer cells to treatment by fulvestrant, a commonly used drug for estrogen-receptor-positive metastatic breast cancer. The study suggests that using an agent that can hit multiple Bcl2 proteins will be more effective in overcoming tumor resistance.
Researchers at UT Southwestern Medical Center have found that an experimental drug, imetelstat, blocks telomerase activity in isolated human cells and tumor-initiating cells from glioblastoma and prostate cancer patients. The drug shows promise in fighting the diseases by inhibiting telomerase activity.
Researchers identified a strategy to target human breast cancer stem cells by blocking the protein CXCR1. The approach selectively depleted cancer stem cells in mice xenotransplanted with human breast cancer cells, leading to reduced tumor growth and metastasis. This finding provides hope for women with breast cancer.
A recent study identifies CXCR1 as a crucial protein in targeting human breast cancer stem cells. Inhibiting this protein selectively depletes the cancer stem cell population, leading to reduced tumor growth and metastasis. The findings suggest that strategies targeting CXCR1 may offer a promising approach for treating breast cancer.
Researchers at Purdue University have developed nanoprobes that deliver cancer drugs directly to tumor cells, reducing damage to healthy cells. The nanoprobes mimic the natural delivery system of endosomes and can track their distribution within cells.
Researchers at the University of Texas M. D. Anderson Cancer Center have developed a novel detection method that can identify circulating tumor cells (CTCs) after they undergo epithelial-mesenchymal transition (EMT), rendering them undetectable by current methods.
Researchers at the University of Michigan Comprehensive Cancer Center found that compounds derived from turmeric and pepper can decrease stem cells while having no effect on normal differentiated cells. This suggests a potential role for curcumin and piperine in preventing breast cancer by targeting stem cells.
Researchers use live imaging to study breast cancer cell spread, finding TGFb as the control switch. Single cells break away when TGFb is active, while clumps do so when inactive, limiting spread to local lymphatic system.
Researchers at Johns Hopkins Medicine have discovered a protein called Twist that accurately distinguishes stem cells driving aggressive breast cancer from other cancer cells. The protein's presence alone can flag a tumor cell as a breast cancer stem cell, suggesting new potential for early detection and treatment strategies.
Dr. Shiaw-Yih Lin's research focuses on the DNA damage response, exploring its crucial component replication stress response or RSR. His team aims to identify biomarkers for early detection of defective RSR and develop targeted nanoparticles for diagnosis and treatment.
Increased Mdm2 expression drives more aggressive cancer characteristics in late-stage breast cancers. Targeting Mdm2 may help prevent progression of the disease.
A team of NIST researchers has created a nanotube-antibody combination to detect and destroy aggressive HER2 breast cancer cells, with nearly 100% eradication rates in laboratory tests. The technique uses near-infrared laser light to target and incinerate the cancer cells.
Researchers found that a prolonged exposure to TGF-ß1 causes cancer cells to become even more aggressive and likely to spread. A potential treatment, nutlin3, blocks the cancer-causing effects of long-term TGF-ß1 exposure, preventing metastasis and killing cancer cells.
Researchers have found that the protein ERK cycles between the nucleus and cell proper in breast tissue cells, affecting cell growth and response to growth factors. The oscillations were regular and robust, providing a new insight into the internal signals controlling cell behavior.
Researchers at Winship Cancer Institute have discovered a common switch governing cancer cells' glucose usage, which could lead to new treatments.
Researchers developed a new combination therapy that blocks autophagy in breast cancer cells, leading to increased cell death rates. This approach may help overcome resistance mechanisms in breast cancer, providing a promising treatment option.
Researchers at Cornell University College of Veterinary Medicine have discovered that inactivating the Hus1 gene efficiently kills cells lacking p53, a gene mutated in most human cancers. The study provides an important new understanding of cancer cells and their weaknesses.
A new therapeutic approach targets proliferation of cancer cells without affecting normal cells, showing promise for selective eradication of human cancers. Researchers developed a phenanthridine derived polyADP-ribose polymerase (PARP) inhibitor that efficiently kills breast cancer cells while leaving healthy cells untouched.
Researchers at Rush University Medical Center identified a cellular pathway that explains the link between alcohol and cancer. Alcohol stimulates the epithelial-to-mesenchymal transition, making cancer cells more aggressive and spreading throughout the body.
A new study published in Nature reveals that the loss of a gene called PTEN from surrounding cells can dramatically alter the tumor environment, fostering tumor growth. The findings suggest a new role for PTEN in suppressing cancer development and could lead to entirely new treatments targeting both cancer cells and their surroundings.
Researchers at Georgetown University Medical Center discovered that a gene associated with immunological disorders plays a crucial role in preventing breast cancer. The study suggests that drugs targeting this gene may inadvertently promote breast cancer development.
The American Association for Cancer Research is honoring two leading breast cancer researchers, Robert Weinberg and Charles Perou, at the 32nd annual CTRC-AACR San Antonio Breast Cancer Symposium. The symposium will feature research on metastasis, genetic technology, and molecular subtypes of breast cancer.
Scientists at the University of York have successfully silenced a gene that appears essential to cancer cell survival, leaving healthy cells unaffected. This discovery suggests that certain genes may be specific to cancer cells, paving the way for the development of new cancer treatments with fewer side effects.
Researchers found that NEDD9 protein is required for aggressive breast cancer growth, and its absence limits the appearance of metastatic breast cancer. The study suggests that NEDD9 could serve as a biomarker for aggressive forms of breast cancer.
Researchers have discovered that Fanconi anemia and breast cancer proteins are controlled by replication at DNA damage sites. This finding highlights a new paradigm for understanding the repair of DNA crosslinks in both FA and BRCA cancer proteins.
Researchers discover that overexpression of 14-3-3ζ launches a molecular cascade that removes bonds holding premalignant cells together, converting them to highly mobile mesenchymal-like cells. This process is recognized as a crucial step in metastasis and can be identified using biomarkers.
Researchers at the University of New South Wales found high-risk HPV strains in 39% of ductal carcinoma in situ and 21% of invasive ductal carcinoma breast cancer specimens. The study suggests a causal role for HPV in many breast cancers, establishing the possibility of preventing some breast cancers by vaccination against HPV.
Research suggests that PPAR-γ agonist 15d-PGJ2 inhibits gastric cancer cell growth through a mechanism independent of PPAR-γ. The study's findings support the potential therapeutic role of PPAR-γ agonists in chemoprevention or chemotherapy of gastric malignancies.
Researchers at Harvard Medical School found that separated cells lose energy-harvesting ability and eventually starve due to metabolic defects. Increasing antioxidant activity restores metabolic function, allowing cells to use alternative energy sources, raising the possibility of early-stage tumor cell survival.
Researchers have created a new technology that allows for the localization of nanoliter droplets of reagents over cells in high-density arrays without physical walls or dry substrates. This enables the use of hundreds of times less reagent and maintains cell viability in wet environments, revolutionizing gene expression studies.
Researchers discovered a first compound that targets cancer stem cells directly, reducing breast cancer stem cells by over 100-fold. Salinomycin slows tumor growth and seed tumors in mice, highlighting a new avenue for cancer therapy development.
Researchers discover a chemical that selectively kills cancer stem cells, which enable cancers to spread and reemerge after treatment. The compound, salinomycin, shows surprising potency against laboratory-created and naturally occurring cancer stem cells.
Researchers at Stanford University School of Medicine have discovered a common molecular pathway used by breast cancer stem cells and normal breast stem cells when reproducing. Increasing the levels of miR-200c suppresses their ability to divide and reproduce.
Researchers have discovered a gene signature in breast cancer stem cells that could be used to develop new drugs. The study found that this gene signature is enriched in human breast tumors after hormone treatment, making it a promising target for therapeutic intervention.
Researchers at Stanford's School of Medicine identified human bladder cancer stem cells and revealed how they work to escape the body's natural defenses. The discovery may be a valuable therapeutic target for many types of cancers.
A study by Walter and Eliza Hall Institute scientists suggests that luminal progenitor cells, the 'daughters' of breast stem cells, are likely responsible for basal-like breast tumours in women with BRCA1 mutations. The research, published in Nature Medicine, represents a major shift in understanding how breast cancer develops.
Researchers at Genome Institute of Singapore identify RCP as a novel breast cancer promoting gene that functionsally contributes to aggressive breast cancer behaviour. Over-expression of RCP is positively correlated with cancer recurrence in patients, and silencing the gene significantly diminishes tumour formation and metastasis.
A new study led by Memorial Sloan-Kettering Cancer Center researchers identifies the genetic function that enables breast cancer cells to survive and spread in the bone marrow. The findings support the development of therapies targeting this survival capacity, which could prevent metastasis and improve patient outcomes.
Researchers discovered that certain carbohydrates on normal cells and enzymes like β3GnT1 function as tumor suppressors. Upregulation of β3GnT1 reduced tumor activity and metastasis in breast and prostate cancers. The study provides new insights into the role of complex carbohydrates in cancer.
Researchers have identified key signals supporting long-term survival of breast cancer cells after they spread to the bone marrow. The study found that activity of a cancer-related enzyme called Src is associated with late-onset bone metastasis and promotes cell survival.
Researchers at Dana-Farber Cancer Institute discovered a cancer-causing gene, GOLPH3, which can spur cancer cell growth and is linked to effective treatment with rapamycin. The study also found that high levels of the protein may serve as a biomarker for tumors responding well to this chemotherapy drug.
Researchers have developed novel compounds that absorb by cancer cells and release nitric oxide upon specific light wavelengths, inducing apoptosis and killing tumor cells. The compounds, called dye-sensitized ruthenium nitrosyls, offer a localized delivery of high concentrations of nitric oxide without causing inflammation.
Researchers at Northwestern University have developed a novel method to separate cancer cells from normal cells by directing their movement along preferred directions. The technique utilizes ratcheting technology and has the potential to create a
Researchers at Whitehead Institute for Biomedical Research discovered a microRNA, miR-31, that inversely correlates with metastasis in breast cancer. Increasing miR-31 levels can help predict patient prognoses and potentially aid in the development of targeted therapies.
Researchers found that Stat5a protein has a mixed function in breast cancer development, promoting growth of certain precancerous lesions but also protecting mammary cells from carcinogenic exposure. The study highlights the importance of understanding breast cancer heterogeneity when testing new therapeutic targets.
Researchers at VBI developed a new one-step bioanalytical approach to profile protein changes in breast cancer cells treated with hormones or cancer drugs. The method identified 16 differentially expressed proteins, linking them to cancer-related biological processes.
PTEN is often inactivated in breast cancer, leading to poor patient outcomes. Researchers found that a drug called perifosine specifically targets the breast cancer stem cell population by inhibiting the Akt pathway, reducing tumor-forming cells by up to 90%.
Researchers at U-M Comprehensive Cancer Center found that PTEN pathway affects growth of breast cancer stem cells and discovered a 90% reduction in stem cell population with perifosine treatment. This study suggests that targeting this pathway may improve current therapies for breast cancer
A protein that maintains cell 'stemness' has been linked to various advanced human cancers, including liver cancer, ovarian cancer, and Wilm's tumor. Increasing its production can prevent mature tumor-suppressing microRNAs from maturing, leading to a more cancerous state.
Researchers successfully engineer MSCs to deliver cancer-killing protein TRAIL, destroying tumor cells while sparing normal cells. In mouse models, the genetically modified stem cells reduced breast and lung cancer growth by up to 80%.
The study reveals how a single event can trigger the collapse of molecular fences, leading to the inactivation of tumor suppressor genes and the initiation of tumorigenesis. The researchers discovered that the loss of PARlation marks on CTCF protein allows it to fail to regulate critical genes, including p16 and RASSF1A.
Researchers found that the gene ZBP1 is silenced in metastasizing breast cancer cells due to a methyl group attachment, leading to increased cell migration and proliferation. The study suggests potential drug targets for preventing metastasis and may help predict breast tumor outcomes by identifying signs of ZBP1 silencing.
Researchers at UNC identified the p18 gene as a potential cause of luminal-type breast cancers, which account for 70-80% of all cases. The study found that defects in this gene lead to uncontrolled cell growth and cancer.
Research at Memorial Sloan Kettering Cancer Center identifies three genes mediating breast cancer's spread to the brain. COX2 and HB-EGF prime cells for entrance, while ST6GALNAC5 enables passage through the blood-brain barrier.
A novel gene called DEAR1 is associated with increased risk of local recurrence in young women with breast cancer. The discovery could lead to a new prognostic marker and guide treatment decisions.